Health Canada Approves Mounjaro for Heart Protection

The approval covers adults with type 2 diabetes and established cardiovascular disease, such as a past heart attack or stroke.

Updated on Nov. 19, 2026 in Diseases

Plain unlabeled injection pen resting on a pale wooden tray beside a folded white cloth in a bright, uncluttered clinic room.
Health Canada approved Mounjaro on November 18, 2026, to lower heart attack, stroke, and heart-related death risk in adults with type 2 diabetes and existing heart disease. AI Illustration. Upload story photo >

Live Poll

Would you ask your doctor about a heart-protective diabetes medicine?

Health Canada has approved Mounjaro to lower the risk of heart attack, stroke and heart-related death in adults with type 2 diabetes and established cardiovascular disease. Eli Lilly Canada announced the decision on November 18, 2026.

Why it matters

Heart disease and diabetes are closely linked, and a global review found 32.2% of people with type 2 diabetes also had cardiovascular disease. The approval gives Canadian adults with both conditions a once-weekly option aimed at reducing major heart events.

The approval rests on a Phase 3 trial of more than 13,000 adults with type 2 diabetes and heart disease followed for about four years, which compared Mounjaro directly with Trulicity rather than a placebo. Mounjaro's 8% lower rate of major heart events versus Trulicity was not large enough to prove superiority.

The players

Health Canada

Health Canada is the federal department responsible for regulating drugs and health products sold in Canada, including approving new indications for existing medications.

Eli Lilly Canada

Eli Lilly Canada is the Canadian arm of the U.S.-based pharmaceutical company Eli Lilly and Company, which developed and markets Mounjaro.

The details

Mounjaro is a once-weekly injection that acts on the GIP and GLP-1 gut hormones and was first approved in Canada to improve blood sugar control in type 2 diabetes. The most common side effects were digestive problems such as nausea and diarrhea, usually mild to moderate and mostly occurring while the dose was being increased. The heart indication applies to adults only.

Timeline

  1. 2025: SURPASS-CVOT results were published in The New England Journal of Medicine.

  2. November 18, 2026: Eli Lilly Canada announced the Health Canada approval.

Health Landscape

The approval extends the SURPASS-CVOT trial from a 2025 journal publication into a Canadian regulatory indication, adding a heart-protection claim to Mounjaro's earlier blood sugar approval. It comes as cardiovascular risk management is becoming a central goal of diabetes treatment, not just glucose control.

Adults with type 2 diabetes and established heart disease may now have a once-weekly option with a heart-protection indication, though treatment decisions should be made with a physician. Common side effects such as nausea and diarrhea are usually mild to moderate and tend to occur while the dose is being increased.

The takeaway

Heart protection is becoming a central part of diabetes care, so people with type 2 diabetes and existing heart disease can ask their doctor whether a heart-focused treatment option fits their situation.

Further reading

Explore more on Diabetes and how new treatments are reshaping care for people living with the condition.

Source note: This article includes information reported by Medindia.

Live Poll

Would you ask your doctor about a heart-protective diabetes medicine?